Moderna and Merck's Personalized mRNA Vaccine Cuts Melanoma Recurrence
Moderna and Merck have reported that their personalized mRNA cancer vaccine, tested in a large late-stage trial, significantly reduced melanoma recurrence, marking a major advance in cancer treatment and vaccine technology.
Read the full story → · Latest coverage 26 Aug 2026, 1:00 am UTC
Key moments · 7
Moderna's experimental mRNA cancer treatment progresses
Global News ↗Moderna and Merck shares soar on mRNA cancer vaccine news
Axios ↗Moderna, Merck cancer vaccine shows promise in late-stage trial
CNBC International ↗Landmark trial: mRNA therapy cuts odds of skin cancer return
Scientific American Content: Global Science ↗Moderna cancer vaccine stops melanoma returning
Nature ↗This mRNA vaccine could prevent deadliest skin cancer
CBS Top Stories ↗How a personalised cancer vaccine could cut risk of death by half
Indian Express ↗
